Alkermes to Report Second Quarter Financial Results on July 29, 2025

Rhea-AI Summary

Alkermes (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has scheduled its second quarter 2025 financial results conference call and webcast for July 29, 2025, at 8:00 a.m. ET.

The company specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders such as narcolepsy and idiopathic hypersomnia. Alkermes maintains operations across Ireland, Massachusetts, and Ohio.

News Market Reaction – ALKS

+1.21%

+1.21% Session move

In the trading session that priced this news, ALKS gained 1.21%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-second-quarter-financial-results-on-july-29-2025-302505916.html

SOURCE Alkermes plc

FAQ

When will Alkermes (ALKS) report Q2 2025 earnings?

Alkermes will report Q2 2025 earnings on Tuesday, July 29, 2025 at 8:00 a.m. ET (1:00 p.m. BST).

How can investors access Alkermes' Q2 2025 earnings call?

Investors can access the webcast on the Investors section of Alkermes' website or dial +1 877 407 2988 (U.S.) or +1 201 389 0923 (international).

What therapeutic areas does Alkermes (ALKS) focus on?

Alkermes focuses on neuroscience, developing treatments for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and has pipeline candidates for narcolepsy and idiopathic hypersomnia.

Where are Alkermes' main operations located?

Alkermes is headquartered in Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.